Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX(®)) and a tetanus monovalent vaccine in healthy adults: New considerations for the management of patients with tetanus-prone injuries

In adults with a tetanus-prone injury, combined vaccines such as Tdap-IPV (REPEVAX(®)) can boost immunity against several diseases simultaneously. This Phase IIIb, parallel-group, open-label trial compared antibody responses to Tdap-IPV and tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur(®...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurichesse, Henri, Zimmermann, Ulrich, Galtier, Florence, Launay, Odile, Duval, Xavier, Richard, Patrick, Sadorge, Christine, Soubeyrand, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656080/
https://www.ncbi.nlm.nih.gov/pubmed/23032160
http://dx.doi.org/10.4161/hv.22083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656080/
https://www.ncbi.nlm.nih.gov/pubmed/23032160
http://dx.doi.org/10.4161/hv.22083

Ejemplares similares